Characteristics of Primary and Plasmatic Hemostasis in Preeclampsia

Study Overview
=================
Brief Summary
-----------------
The study aims to investigate the impact of preeclampsia on hemostasis.

Detailed Description
-----------------
In comparison to healthy pregnant women and non-pregnant woman, this study analyses parameters of primary hemostasis and plasmatic coaguation in preeclamptic pregnant woman. Detailed analyses of the platelet function is performed using the Multiple Electrode Aggregometry, detailed analyses of the plasmatic coagulation syste is performed by isolated coaguation factor analyses and conventional coagulation analyses.

Official Title
-----------------
Characteristics of Primary and Plasmatic Hemostasis in Preeclampsia - a Cross-sectional Study

Conditions
-----------------
Coagulation Disorder, Blood, Platelet Function

Intervention / Treatment
-----------------
* Diagnostic Test: Aggregometry, Monitoring of plasmatic hemostasis


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Platelet count > 100 / nll In study group and control group 1: Week of Pregnancy: 35-40 in control group 2: healthy, not pregnant woman Exclusion Criteria: Hereditary coagulopathy Missing content of the patient / proband Eclampsia HELLP syndrome CRP > 1 mg/dl Fever (> 38°C)

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 40 Years

Sexes Eligible for Study
-----------------
Female

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Pregnant Preeclampsia<br>Pregnant between 35th and 40th week of pregnancy Preeclampisa Intervention: Aggregometry, Monitoring of plasmatic hemostasis: Aggregometry and conventional coagulation testing after blood sampling in the context of routinely performed blood sampling | Diagnostic Test: Aggregometry, Monitoring of plasmatic hemostasis<br>* Multiple Electrode Aggregometry using the Multiplate system Coagulation factor analyses (FXIII, FVIII, vWF) Parameters of conventional coagulation testing (aPTT, INR, Platelet count)<br>|
| Pregnant No-Preeclampsia<br>Control Group 1 Pregnant between 35th and 40th week of pregnancy No Preeclampsia Healthy Intervention: Aggregometry, Monitoring of plasmatic hemostasis: Aggregometry and conventional coagulation testing after blood sampling in the context of routinely performed blood sampling | Diagnostic Test: Aggregometry, Monitoring of plasmatic hemostasis<br>* Multiple Electrode Aggregometry using the Multiplate system Coagulation factor analyses (FXIII, FVIII, vWF) Parameters of conventional coagulation testing (aPTT, INR, Platelet count)<br>|
| Not Pregnant<br>Control group 2 Healthy and not pregnant control group Intervention: Aggregometry, Monitoring of plasmatic hemostasis: Aggregometry and conventional coagulation testing after blood sampling. | Diagnostic Test: Aggregometry, Monitoring of plasmatic hemostasis<br>* Multiple Electrode Aggregometry using the Multiplate system Coagulation factor analyses (FXIII, FVIII, vWF) Parameters of conventional coagulation testing (aPTT, INR, Platelet count)<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Area under the aggregation curve in the ADPtest of the Multiple Electrode Aggregometry | ADP induced platelet aggregation | Between 35th and 40th week of pregnancy; in control group 2 (not pregnant) within 1 week after inclusion into the study | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Area under the aggregation curve in the ASPItest of the Multiple Electrode Aggregometry | Arachidonic acid induced platelet aggregation | Between 35th and 40th week of pregnancy; in control group 2 (not pregnant) within 1 week after inclusion into the study | 
| Area under the aggregation curve in the TRAPtest of the Multiple Electrode Aggregometry | Thrombin induced platelet aggregation | Between 35th and 40th week of pregnancy; in control group 2 (not pregnant) within 1 week after inclusion into the study | 
| Parameters of plasmatic coagulation system | von Willebrand Factor, Factor VIII, Factor XIII, parameter of conventional coagulation testing (apTT, INR, platelet count, Fibrinogen) | Between 35th and 40th week of pregnancy; in control group 2 (not pregnant) within 1 week after inclusion into the study | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Aggregometry